Lonza
Lonza Group AG, commonly referred to as Lonza, is a leading global provider of integrated solutions for the pharmaceutical, biotechnology, and specialty ingredients sectors. Headquartered in Switzerland (CH), Lonza operates extensively across Europe, North America, and Asia, delivering innovative products and services that cater to diverse industry needs. Founded in 1897, Lonza has achieved significant milestones, including advancements in cell and gene therapy manufacturing. The company is renowned for its high-quality contract development and manufacturing services (CDMO), as well as its extensive portfolio of active pharmaceutical ingredients (APIs) and custom manufacturing solutions. Lonza's commitment to sustainability and cutting-edge technology positions it as a market leader, consistently recognised for its contributions to the life sciences and healthcare industries.
DitchCarbon Score
How does Lonza's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Lonza's score of 73 is higher than 85% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Lonza's reported carbon emissions
In 2024, Lonza reported total carbon emissions of approximately 2,334,000,000 kg CO2e, with Scope 1 emissions at about 319,000,000 kg CO2e, Scope 2 emissions at approximately 137,000,000 kg CO2e (market-based), and a significant Scope 3 contribution of around 1,878,000,000 kg CO2e. This represents a decrease from 2023, where total emissions were about 2,459,000,000 kg CO2e, with similar breakdowns across the scopes. Lonza has set ambitious climate commitments, aiming for a 42% reduction in absolute Scope 1 and 2 GHG emissions by 2030, using a 2021 baseline. This target is aligned with the Science Based Targets initiative (SBTi) and includes a commitment that 79% of its suppliers will also have science-based targets by 2028. Additionally, the company aims to reduce energy and waste intensity by 50% by 2030 compared to 2018 levels. The company is headquartered in Switzerland (CH) and is actively pursuing a comprehensive climate plan to achieve net-zero emissions by 2050 or earlier. Lonza's efforts reflect a strong commitment to sustainability within the pharmaceuticals and biotechnology sector, addressing both operational emissions and supply chain impacts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 574,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 348,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Lonza is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
